Interview: Fabrizio Greco – General Manager, AbbVie Italy
Fabrizio Greco, General Manager at AbbVie Italy, discusses the successful launch of the company’s new Hepatitis C treatment, how AbbVie is seeking to position itself as a partner to the…
Recipharm was established in Sweden in 1995 and has since then grown to become a leading Contract Development and Manufacturing Organisation (CDMO) and is headquartered close to Stockholm.
Today, Recipharm operates 25 facilities in 10 countries (France, Germany, India, Italy, Israel, Portugal, Spain, Sweden, USA and the UK) covering most of the pharmaceutical dosage forms. Recipharm employs around 4.000 people and is listed on NASDAQ Stockholm.
In October 2014 Recipharm acquired Italian Corvette Group including all the operating companies based in Milan (Biologici Italia Laboratories, Edmond Pharma, Liosintex).
In February 2016 Mitim, located in Brescia, was acquired.
In Italy Recipharm operates four manufacturing facilities, specialized in parenterals of freeze-dried and liquid vials and ampoules, lyophilisation of sterile beta-lactam antibiotics in bulk, filling of beta-lactams powder, APIs synthesis oral solid form, Erdosteine business (API synthesis and finished dosages).
Recipharm has the competence, flexibility and facilities to take on challenging projects which require custom tailored processes. With a broad range of expertise and technologies available, Recipharm offers support and services ranging from development and procurement to full-scale manufacturing, distribution, technology transfer and stability studies. In addition to human pharmaceuticals, Recipharm can also supply medical devices and veterinary products.
Please visit our web site: www.recipharm.com
Fabrizio Greco, General Manager at AbbVie Italy, discusses the successful launch of the company’s new Hepatitis C treatment, how AbbVie is seeking to position itself as a partner to the…
Enrique Hausermann, CEO of EG, the Stada Group’s Italian affiliate for its generics business, discusses the progress the company has made since 2009, the promising areas for growth he sees…
CFCII’s Director provides us with an overview of the services offered to French and Italian companies by the Chamber, as well as her perceptions about investments between the two countries,…
Alberto Gugliemo, President of the Carlo Besta Institute in Milan, shares the changing perception of neurological diseases and neurological science in Italy, the nature of the institute’s collaboration with the…
Francesco Carugi, Managing Director at Grifols Italy, discusses the company’s presence in the plasma, plasma products and plasma diagnostics segments, the impact of the liberalization of the Italian plasma market on…
Dr. Giorgio Pisani, President and CEO of IBSA Italy, talks about his founding of the company in 2001 and its rapid growth in the market through a combination of organic…
Prof. Walter Ricciardi has just been appointed as the new president for the Italian National Institute of Health (ISS). He explains his priorities since taking office, the crucial role the…
Paolo Casati, general manager for Santen’s new affiliate in Italy, discusses the company’s first full year in the country, its aims for contributing to the global group’s 2020 Vision by…
Paolo Cionini, General Manager of LEO Pharma Italy, discusses the initial challenges of setting up the Italian affiliate during the height of the global financial crisis in 2011, the company’s…
Sofia Astrid Pennacchi, Secretary General of the British Chamber of Commerce for Italy, discusses the various services the Chamber offers its members, the positive effects the Expo has had on…
Giulio Volpe, Managing Director of Lundbeck’s Italian API’s production plant, discusses what is leading multinational companies to relocate their production to Italy, the value the Italian plant can offer the…
Enrico Allievi, President of the Italian OTC (Over The Counter) association, Assosalute, talks about the state of the OTC market in Italy, as well as the association’s role in creating…
See our Cookie Privacy Policy Here
